Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Jennifer, Colangelo"'
Autor:
Michael D. Aleo, Jiri Aubrecht, Paul D. Bonin, Deborah A. Burt, Jennifer Colangelo, Lina Luo, Shelli Schomaker, Rachel Swiss, Simon Kirby, Greg C. Rigdon, Pinky Dua
Publikováno v:
Pharmacology Research & Perspectives, Vol 7, Iss 1, Pp n/a-n/a (2019)
Abstract During a randomized Phase 1 clinical trial the drug candidate, PF‐04895162 (ICA‐105665), caused transaminase elevations (≥grade 1) in six of eight healthy subjects treated at 300 mg twice daily for 2‐weeks (NCT01691274). This was une
Externí odkaz:
https://doaj.org/article/1c3b4feee3294f4685dafba7fa2a28f4
Autor:
Simon Lavallée, Adam D. Aulbach, Mehrdad Ameri, Daniela Ennulat, Jennifer Colangelo, Marie-Soleil Piche, Laura Boone, Florence Poitout
Publikováno v:
Toxicologic Pathology. 46:847-856
Method validation is a cornerstone on which biomarker development and utilization rest. However, given the abundance of biomarker candidates that are being identified and characterized, validation of these entities for the use in nonclinical studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4c2ba8e5947ed086dba0a0156ceac44
https://doi.org/10.1177/0192623318801571
https://doi.org/10.1177/0192623318801571
Autor:
Jennifer Colangelo
Publikováno v:
Toxicologic Pathology. 45:977-982
Mass spectrometry (MS) has become a key platform in the clinical pathology laboratory and is being used more frequently for clinical pathology assessments in preclinical species for drug development studies. MS assays are being utilized for some trad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bdeaf3901173fbcf060261ceab3191f
https://doi.org/10.1177/0192623317737240
https://doi.org/10.1177/0192623317737240
Autor:
Rachel Roach, Joseph Sergi, Mark Horn, Mike Favis, Jeanne Sue Magram, Victoria Markiewicz, William B. Snyder, Kymberly Levine, Jennifer Colangelo, Jean Chamoun, Moosa Mohammadi, Jacqueline Vekich, Dikran Aivazian, Edwin Berryman, William J. Reagan, Cedo M. Bagi, Kristen Johnson, Anthony J. Coyle, Brian Robert Miller, Xianjun Cao, Thomas P. Brown
Publikováno v:
Journal of Bone and Mineral Research. 32:2062-2073
Fibroblast growth factor 23 (FGF23) is the causative factor of X-linked hypophosphatemia (XLH), a genetic disorder effecting 1:20,000 that is characterized by excessive phosphate excretion, elevated FGF23 levels and a rickets/osteomalacia phenotype.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7a0463bfb83c9e8e3ec98297dad41ba
https://doi.org/10.1002/jbmr.3197
https://doi.org/10.1002/jbmr.3197
Autor:
William J. Reagan, David W. Clarke, George Hu, Richard Perry, Ingrid D. Pardo, K Nasir Khan, Jennifer Colangelo, Rani S. Sellers, Victoria Markiewicz, Cynthia M. Rohde
Publikováno v:
Toxicologic Pathology. 45:416-426
Despite the use of rabbits in biomedical research, including regulatory toxicology and cardiovascular studies, little data exist on heart findings in this species. This study was designed to document myocardial findings in female rabbits and the impa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36fbe853424f90c311e588e5a5e9105f
https://doi.org/10.1177/0192623317700519
https://doi.org/10.1177/0192623317700519
Autor:
Shelli J. Schomaker, Pinky Dua, Lina Luo, Jennifer Colangelo, Greg C. Rigdon, Rachel Swiss, Simon Kirby, Jiri Aubrecht, Michael D. Aleo, Deborah A. Burt, Paul D. Bonin
Publikováno v:
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives, Vol 7, Iss 1, Pp n/a-n/a (2019)
Pharmacology Research & Perspectives, Vol 7, Iss 1, Pp n/a-n/a (2019)
During a randomized Phase 1 clinical trial the drug candidate, PF‐04895162 (ICA‐105665), caused transaminase elevations (≥grade 1) in six of eight healthy subjects treated at 300 mg twice daily for 2‐weeks (NCT01691274). This was unexpected s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfe4796207cf58d755785084f24488e8
https://pubmed.ncbi.nlm.nih.gov/30784208
https://pubmed.ncbi.nlm.nih.gov/30784208
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 99:106595
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2d88ad1ae9e83a8d83562c25e90f90f
https://doi.org/10.1016/j.vascn.2019.05.114
https://doi.org/10.1016/j.vascn.2019.05.114
Autor:
Philip Gerwin, Peter Harris, Jennifer Colangelo, Ricardo Fernandez, Isaac Rosado, Corey Petrella, Todd Wisialowski, Laura Singer
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 99:106595
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18a56ccaa3bfcc1ebd4bea97ec6221d9
https://doi.org/10.1016/j.vascn.2019.05.153
https://doi.org/10.1016/j.vascn.2019.05.153
Autor:
Kristen, Johnson, Kymberly, Levine, Joseph, Sergi, Jean, Chamoun, Rachel, Roach, Jacqueline, Vekich, Mike, Favis, Mark, Horn, Xianjun, Cao, Brian, Miller, William, Snyder, Dikran, Aivazian, William, Reagan, Edwin, Berryman, Jennifer, Colangelo, Victoria, Markiewicz, Cedo M, Bagi, Thomas P, Brown, Anthony, Coyle, Moosa, Mohammadi, Jeanne, Magram
Publikováno v:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 32(10)
Fibroblast growth factor 23 (FGF23) is the causative factor of X-linked hypophosphatemia (XLH), a genetic disorder effecting 1:20,000 that is characterized by excessive phosphate excretion, elevated FGF23 levels and a rickets/osteomalacia phenotype.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c5cb78ea0e3a2480986e3dad5a1b35db
https://pubmed.ncbi.nlm.nih.gov/28600887
https://pubmed.ncbi.nlm.nih.gov/28600887
Autor:
Sharon A. Sokolowski, Steven Duddy, Kay A. Criswell, Zbigniew Wojcinski, Michael T. Lawton, Joseph T. Brady, Christopher Somps, Ramin Rahbari, Dennis C. Morse, Marc D. Roy, Jennifer Colangelo, Leslie A. Obert, Jon C. Cook, David G. Pegg, Petra H. Koza-Taylor, Timothy Anderson, Kimberly A. Navetta
Publikováno v:
Toxicological Sciences. 128:42-56
The preceding article identified key components of pregabalin's mode of action on nongenotoxic hemangiosarcoma formation in mice, including increased serum bicarbonate leading to decreased respiratory rate, increased blood pH, increased venous oxygen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af0df5126d3a40653d7d787746176f2a
https://doi.org/10.1093/toxsci/kfs148
https://doi.org/10.1093/toxsci/kfs148